NRx Pharmaceuticals (NRXP) Expected to Announce Quarterly Earnings on Wednesday

Posted by ABMN Staff on Mar 24th, 2025

NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) is projected to release its earnings data after the market closes on Wednesday, March 26th. Analysts expect NRx Pharmaceuticals to post earnings of ($0.30) per share for the quarter.

NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) last issued its quarterly earnings results on Friday, March 14th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.10). On average, analysts expect NRx Pharmaceuticals to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

NRx Pharmaceuticals Price Performance

Shares of NASDAQ NRXP opened at $2.08 on Monday. The stock has a market cap of $35.19 million, a PE ratio of -0.97 and a beta of 1.22. NRx Pharmaceuticals has a 1 year low of $1.10 and a 1 year high of $6.01. The firm has a fifty day moving average price of $2.82 and a 200-day moving average price of $2.03.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on NRXP shares. HC Wainwright reiterated a “buy” rating and issued a $19.00 price target on shares of NRx Pharmaceuticals in a research note on Thursday. Ascendiant Capital Markets increased their target price on NRx Pharmaceuticals from $44.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, December 2nd. Finally, D. Boral Capital reissued a “buy” rating and issued a $31.00 price target on shares of NRx Pharmaceuticals in a report on Monday, March 17th.

Read Our Latest Report on NRx Pharmaceuticals

NRx Pharmaceuticals Company Profile

(Get Free Report)

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.